Skip to main content
. 2019 Aug 15;3(16):2448–2452. doi: 10.1182/bloodadvances.2019000064

Figure 2.

Figure 2.

Dinaciclib enhances NK-cell killing of leukemic target cells in human AML cell line xenograft mice. NSG mice were conditioned, engrafted with luciferase-expressing HL60 AML cells, and then treated with dinaciclib and/or enriched primary human NK cells from healthy donors as outlined (A). Mice that received human NK cells also received 5 µg of recombinant human IL15 (rhIL15) 3 times per week. Leukemic burden was analyzed by bioluminescent imaging (B) and peripheral blood was obtained to enumerate human NK-cell numbers (human CD45+CD3−CD56+ cells) (C) at 28 days after NK-cell injection. Error bars represent mean ± standard error of the mean. *P < .05 using a paired Student t test corrected for multiple comparisons. IP, intraperitoneally; n.s., nonsignificant P value.